-
1
-
-
85028154920
-
-
Abbott Laboratories, Last revised September 2012. (accessed 17 Apr 2013)
-
Abbott Laboratories. Humira (adalimumab) [highlights of prescribing information]. Last revised September 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125057s232lbl.pdf (accessed 17 Apr 2013).
-
Humira (Adalimumab) [Highlights of Prescribing Information]
-
-
-
2
-
-
85028150936
-
-
UCB Inc., Last revised November 2012, (accessed 17 Apr 2013)
-
UCB Inc. Cimzia (certolizumab) [highlights of prescribing information]. Last revised November 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125160s189lbl.pdf (accessed 17 Apr 2013).
-
Cimzia (Certolizumab) [Highlights of Prescribing Information]
-
-
-
3
-
-
85028156216
-
-
Amgen Wyeth manufactured by Immunex, Last revised December 2012, (accessed 17 Apr 2013)
-
Amgen Wyeth, manufactured by Immunex. Enbrel (etanercept) [highlights of prescribing information]. Last revised December 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/103795s5507lbl.pdf (accessed 17 Apr 2013).
-
Enbrel (Etanercept) [Highlights of Prescribing Information]
-
-
-
4
-
-
85028150936
-
-
Janssen Biotech, Inc., Last revised March 2013, (accessed 17 Apr 2013)
-
Janssen Biotech, Inc. Remicade (infliximab) [highlights of prescribing information]. Last revised March 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/103772s5345lbl.pdf (accessed 17 Apr 2013).
-
Remicade (Infliximab) [Highlights of Prescribing Information]
-
-
-
5
-
-
85028150936
-
-
Janssen Biotech, Inc., Last revised November 2012, (accessed 17 Apr 2013)
-
Janssen Biotech, Inc. Simponi (golimumab) [highlights of prescribing information]. Last revised November 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125289s070lbl.pdf (accessed 17 Apr 2013).
-
Simponi (Golimumab) [Highlights of Prescribing Information]
-
-
-
6
-
-
79953018875
-
Adverse effects of biologics: A network meta-analysis and Cochrane overview
-
Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2: CD008794.
-
(2011)
Cochrane Database Syst Rev
, vol.2
, pp. CD008794
-
-
Singh, J.A.1
Wells, G.A.2
Christensen, R.3
-
7
-
-
78649645500
-
Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
-
Kay J, Rahman MU. Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid 2010;4:159-70.
-
(2010)
Core Evid
, vol.4
, pp. 159-170
-
-
Kay, J.1
Rahman, M.U.2
-
8
-
-
42449157502
-
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study
-
Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 964-975
-
-
Kay, J.1
Matteson, E.L.2
Dasgupta, B.3
-
9
-
-
68049099274
-
Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
-
Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 2272-2283
-
-
Emery, P.1
Fleischmann, R.M.2
Moreland, L.W.3
-
10
-
-
84887089482
-
Golimumab, a human anti-TNF monoclonal antibody, injected subcutaneously every 4 weeks in MTX-naïve patients with active rheumatoid arthritis: 1-year and 2-year clinical, radiological, and physical function findings of a Phase 3, multicenter, randomized, double-blind, placebo-controlled study
-
Emery P, Fleischmann RM, Doyle MK, et al. Golimumab, a human anti-TNF monoclonal antibody, injected subcutaneously every 4 weeks in MTX-naïve patients with active rheumatoid arthritis: 1-year and 2-year clinical, radiological, and physical function findings of a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res (Hoboken) 2013;65:1732-1742.
-
(2013)
Arthritis Care Res (Hoboken)
, vol.65
, pp. 1732-1742
-
-
Emery, P.1
Fleischmann, R.M.2
Doyle, M.K.3
-
11
-
-
67449133560
-
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study
-
Keystone E, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 789-796
-
-
Keystone, E.1
Genovese, M.C.2
Klareskog, L.3
-
12
-
-
77953701867
-
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
-
Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1129-1135
-
-
Keystone, E.1
Genovese, M.C.2
Klareskog, L.3
-
13
-
-
84879891418
-
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: Results through 2 years of the GO-FORWARD study extension
-
Keystone E, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol 2013;40:1097-1103.
-
(2013)
J Rheumatol
, vol.40
, pp. 1097-1103
-
-
Keystone, E.1
Genovese, M.C.2
Hall, S.3
-
14
-
-
67650379733
-
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
-
Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.
-
(2009)
Lancet
, vol.374
, pp. 210-221
-
-
Smolen, J.S.1
Kay, J.2
Doyle, M.K.3
-
15
-
-
84866104476
-
Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: Results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
-
Smolen JS, Kay J, Landewé RB, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis 2012;71:1671-9.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 1671-1679
-
-
Smolen, J.S.1
Kay, J.2
Landewé, R.B.3
-
16
-
-
65249137637
-
Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
-
Kavanaugh A, McInnes IB, Mease PJ, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 976-986
-
-
Kavanaugh, A.1
McInnes, I.B.2
Mease, P.J.3
-
17
-
-
84864438913
-
Golimumab in psoriatic arthritis: One year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
-
Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012;64:2504-17.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 2504-2517
-
-
Kavanaugh, A.1
Van Der Heijde, D.2
McInnes, I.B.3
-
18
-
-
84885181527
-
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
-
Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013;72:1777-1785.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 1777-1785
-
-
Kavanaugh, A.1
McInnes, I.B.2
Mease, P.J.3
-
19
-
-
55849108826
-
Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial
-
Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 3402-3412
-
-
Inman, R.D.1
Davis, J.C.2
Van Der Heijde, D.3
-
20
-
-
84859509505
-
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
-
Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2012;71:661-7.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 661-667
-
-
Braun, J.1
Deodhar, A.2
Inman, R.D.3
-
21
-
-
0029044362
-
American College of Rheumatology: Preliminary definition of improvement in rheumatoid arthritis
-
Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
-
(1995)
Arthritis Rheum
, vol.38
, pp. 727-735
-
-
Felson, D.T.1
Anderson, J.J.2
Boers, M.3
-
22
-
-
0021272107
-
Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria
-
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
-
(1984)
Arthritis Rheum
, vol.27
, pp. 361-368
-
-
Van Der Linden, S.1
Valkenburg, H.A.2
Cats, A.3
-
23
-
-
0028575453
-
A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index
-
Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
-
(1994)
J Rheumatol
, vol.21
, pp. 2286-2291
-
-
Garrett, S.1
Jenkinson, T.2
Kennedy, L.G.3
-
24
-
-
84862964714
-
Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: An open-label, randomized study
-
Zhuang Y, Xu Z, Frederick B, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther 2012;34:77-90.
-
(2012)
Clin Ther
, vol.34
, pp. 77-90
-
-
Zhuang, Y.1
Xu, Z.2
Frederick, B.3
-
25
-
-
64549145652
-
-
National Cancer Institute: Surveillance Epidemiology and End Results, (accessed 17 Apr 2013)
-
National Cancer Institute: Surveillance, Epidemiology, and End Results. Overview of the SEER program. http://SEER.cancer.gov/about/overview.html (accessed 17 Apr 2013).
-
Overview of the SEER Program
-
-
-
26
-
-
84863871272
-
Assessing the safety of biologic agents in patients with rheumatoid arthritis
-
Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012;51:v38-47.
-
(2012)
Rheumatology (Oxford)
, vol.51
, pp. v38-v47
-
-
Rubbert-Roth, A.1
-
27
-
-
84874445437
-
Adalimumab: Long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
-
Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 517-524
-
-
Burmester, G.R.1
Panaccione, R.2
Gordon, K.B.3
-
28
-
-
34848816866
-
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
-
Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 1339-1344
-
-
Askling, J.1
Fored, C.M.2
Brandt, L.3
-
29
-
-
33646696885
-
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
-
Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
-
(2006)
JAMA
, vol.295
, pp. 2275-2285
-
-
Bongartz, T.1
Sutton, A.J.2
Sweeting, M.J.3
-
30
-
-
34247218183
-
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists
-
Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 1125-1133
-
-
Curtis, J.R.1
Patkar, N.2
Xie, A.3
-
31
-
-
79951712039
-
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
-
on behalf of the British Society for Rheumatology Biologics Register Control Centre Consortium
-
Galloway JB, Hyrich KL, Mercer LK, et al.; on behalf of the British Society for Rheumatology Biologics Register Control Centre Consortium. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124-31.
-
(2011)
Rheumatology (Oxford)
, vol.50
, pp. 124-131
-
-
Galloway, J.B.1
Hyrich, K.L.2
Mercer, L.K.3
-
32
-
-
78049494652
-
Initiation of rheumatoid arthritis treatments and the risk of serious infections
-
Grijalva CG, Kaltenbach L, Arbogast PG, et al. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 2010;49: 82-90.
-
(2010)
Rheumatology (Oxford)
, vol.49
, pp. 82-90
-
-
Grijalva, C.G.1
Kaltenbach, L.2
Arbogast, P.G.3
-
33
-
-
27744458586
-
Infections in patients with rheumatoid arthritis treated with biologic agents
-
Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 3403-3412
-
-
Listing, J.1
Strangfeld, A.2
Kary, S.3
-
34
-
-
60749125474
-
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents
-
Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
-
(2009)
JAMA
, vol.301
, pp. 737-744
-
-
Strangfeld, A.1
Listing, J.2
Herzer, P.3
-
35
-
-
67549117204
-
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events
-
Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1136-1145
-
-
Leombruno, J.P.1
Einarson, T.R.2
Keystone, E.C.3
-
36
-
-
66449083072
-
Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans
-
Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009;119:1167-77.
-
(2009)
J Clin Invest
, vol.119
, pp. 1167-1177
-
-
Bruns, H.1
Meinken, C.2
Schauenberg, P.3
-
37
-
-
84873197989
-
Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-TNF antibody, in phase 3 clinical trials
-
Hsia EC, Cush JJ, Matteson EL, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-TNF antibody, in phase 3 clinical trials. Arthritis Care Res (Hoboken) 2013;65:309-13.
-
(2013)
Arthritis Care Res (Hoboken)
, vol.65
, pp. 309-313
-
-
Hsia, E.C.1
Cush, J.J.2
Matteson, E.L.3
-
38
-
-
84863217872
-
Interferon-? Release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
-
Hsia EC, Schluger N, Cush JJ, et al. Interferon-? release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012;64:2068-77.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 2068-2077
-
-
Hsia, E.C.1
Schluger, N.2
Cush, J.J.3
-
39
-
-
84868135421
-
Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: Drug-specific comparisons in the Swedish Biologics Register
-
Simard JF, Neovius M, Askling J; for the ARTIS Study Group. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum 2012;64:3502-10.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 3502-3510
-
-
Simard, J.F.1
Neovius, M.2
Askling, J.3
-
40
-
-
34248185611
-
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis
-
Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 670-675
-
-
Jacobsson, L.T.1
Turesson, C.2
Nilsson, J.A.3
-
41
-
-
79961111305
-
Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: A review of long-term data
-
Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of long-term data. J Rheumatol 2011;38:1552-62.
-
(2011)
J Rheumatol
, vol.38
, pp. 1552-1562
-
-
Keystone, E.C.1
-
42
-
-
80053565309
-
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis
-
Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1895-1904
-
-
Mariette, X.1
Matucci-Cerinic, M.2
Pavelka, K.3
-
43
-
-
84865692521
-
Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: A meta-analysis
-
Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA. et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898-908.
-
(2012)
JAMA
, vol.308
, pp. 898-908
-
-
Lopez-Olivo, M.A.1
Tayar, J.H.2
Martinez-Lopez, J.A.3
-
44
-
-
33644892763
-
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
-
Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 692-701
-
-
Baecklund, E.1
Iliadou, A.2
Askling, J.3
-
45
-
-
34248547187
-
The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation
-
Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 1433-1439
-
-
Wolfe, F.1
Michaud, K.2
-
46
-
-
78751685797
-
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
-
Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-30.
-
(2011)
Pharmacoepidemiol Drug Saf
, vol.20
, pp. 119-130
-
-
Askling, J.1
Fahrbach, K.2
Nordstrom, B.3
-
47
-
-
77956021184
-
Demyelinating events in rheumatoid arthritis after drug exposures
-
Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 2010;69:1691-3.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1691-1693
-
-
Bernatsky, S.1
Renoux, C.2
Suissa, S.3
-
48
-
-
78751704873
-
Demyelinating disease in patients treated with TNF antagonists in rheumatology: Data from BIOBADASER, a pharmacovigilance database, and a systematic review
-
Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011;40:330-7.
-
(2011)
Semin Arthritis Rheum
, vol.40
, pp. 330-337
-
-
Fernández-Espartero, M.C.1
Pérez-Zafrilla, B.2
Naranjo, A.3
|